Related Experiment Video

Updated: Jun 5, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease

D'Vesharronne Moore1, Catherine McNeal, Ronald Macfarlane

  • 1Laboratory for Cardiovascular Chemistry, Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.

Biochemical and Biophysical Research Communications
|December 29, 2010
PubMed

Insights

New Apolipoprotein C-I (apoC-I) isoforms were found in individuals with coronary artery disease (CAD). These novel apoC-I variants, potentially from genetic mutations and oxidative stress, were absent in non-CAD subjects.

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Proteomics

Background:

  • Apolipoprotein C-I (apoC-I) is a serum protein linked to high-density lipoproteins (HDL) and triglyceride-rich lipoproteins.
  • Dysregulation of apoC-I may play a role in cardiovascular health.

Purpose of the Study:

  • To investigate apoC-I in high-density lipoprotein (HDL) subfractions from individuals with and without coronary artery disease (CAD).
  • To identify novel apoC-I isoforms and their potential origins in CAD patients.

Main Methods:

  • Mass spectrometry was employed to analyze apoC-I in HDL subfractions.
  • Comparative analysis of apoC-I mass spectra between CAD and non-CAD cohorts.

Main Results:

  • Novel apoC-I isoforms were detected in individuals with CAD, while expected isoforms were absent.
  • Mass spectra from the CAD cohort showed satellite peaks, suggesting oxidative processes.
  • Analysis indicated potential genetic mutations as the source of new apoC-I isoforms.

Conclusions:

  • Coronary artery disease is associated with the presence of novel apoC-I isoforms.
  • Oxidative stress and potential genetic mutations may contribute to the formation of these aberrant apoC-I variants.
  • These findings suggest a potential role for altered apoC-I in the pathophysiology of CAD.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...